Lorediplon
Lorediplon (INN) is a nonbenzodiazepine of the pyrazolopyrimidine family that is being pursued as a treatment for insomnia but has not completed development.[1]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H15FN4O2S |
| Molar mass | 394.422 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
See also
References
- World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2): 179.
| Alcohols |
|
|---|---|
| Barbiturates |
|
| Benzodiazepines |
|
| Carbamates | |
| Flavonoids |
|
| Imidazoles | |
| Kava constituents |
|
| Monoureides |
|
| Neuroactive steroids |
|
| Nonbenzodiazepines | |
| Phenols | |
| Piperidinediones | |
| Pyrazolopyridines | |
| Quinazolinones | |
| Volatiles/gases |
|
| Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators | |
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.